ClinicalTrials.gg
Not yet recruitingNCT07808775CARYANAUpdated Oct 19, 2026

Assessment of the Risk of Zoonotic Infections in Prisons in French Guiana

An observational study in Q Fever, Leptospirosis and Chagas Disease, sponsored by Centre Hospitalier de Cayenne. Not yet recruiting at 1 site in French Guiana. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Centre Hospitalier de Cayenne · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Study summary

The prison system in French Guiana is characterized by severe overcrowding, high levels of promiscuity, poor sanitary conditions, and the documented presence of potential reservoirs or vectors of zoonotic diseases, particularly swallows and rodents.

In French Guiana, several zoonotic diseases have a high incidence or are of particular public health significance, including Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis. Despite this context, the risk of zoonotic diseases in prisons remains poorly documented, even though endemic and epidemic circulation of Q fever has already been described at the French Guiana correctional facility. This study aims to document this risk in a systematic and prospective manner.

The main objective is to assess the prevalence of zoonotic infections (Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis) among inmates at the French Guiana Correctional Facility in 2026-2027.

The other objectives are :

  • To measure the seroprevalence of zoonotic infections among new arrivals at the French Guiana correctional facility;
  • To identify individual risk factors, both within and outside the prison, for acquiring zoonotic infections;
  • To analyze the results in relation to bioclimatic data (wind direction, humidity, precipitation, temperature) The expected benefits will aim to objectively assess the risk of zoonotic diseases within the French Guiana correctional facility, to improve understanding of zoonoses in prison settings, to guide the implementation of appropriate prevention and screening measures, and to contribute to improving health conditions in detention.

It should also strengthen cooperation between health and justice officials as part of an integrated approach to the prevention and management of infectious diseases.

Read the detailed description

The French Guiana Correctional Facility The French Guiana Correctional Facility (CPG) comprises a pretrial detention center characterized by a high turnover of inmates, a detention center, as well as a women's wing, a juvenile wing, and a day-release wing. The prison's theoretical capacity is 616 inmates, but chronic overcrowding is a serious problem, with the number of inmates reaching 1,050 in 2023-170% of its capacity. In 2023, the CPG recorded 1,750 inmates, including 121 women (11.5%)-more than the national average (around 4%). In total, 65% of the inmates were first-time offenders; the average age was 34, and more than half were French nationals. Approximately one-third of the inmates were serving sentences of less than 3 months.

Health care for inmates is part of a health care system that addresses all health issues, whether physical or psychiatric. The reform of the prison healthcare system entrusted the public hospital system with the responsibility for all such care. This care is governed by a methodological guide.

The CPG's Outpatient Consultation and Care Unit (UCSA) is responsible for addressing somatic issues, while the Incarceration Psychiatry Functional Unit (UFPI) handles psychological and psychiatric care. All incarcerated patients receive a routine initial medical examination (VME) within 48 hours of admission to custody, which includes a physical and psychological evaluation. One of the objectives of the VME is to detect any contagious or progressive conditions and to implement appropriate health measures. The inmate is evaluated both physically and psychologically. A clinical examination is performed. Following the consultation, specific treatment is recommended. An STI screening and a frontal chest X-ray are routinely offered, though they are not mandatory. The screening includes serology for syphilis, HIV, hepatitis B, hepatitis C, and HTLV, as well as urinary PCR tests for chlamydia and gonorrhea. The care pathway for detainees is well-structured, and they may also receive medical or paramedical consultations throughout their detention, with the wait time for a consultation depending on the level of urgency. In case of an emergency, the detainee may be transferred to the emergency medical department at the Cayenne Hospital. A routine annual checkup is offered.

The inmate population at the CPG is a vulnerable group facing a multitude of risk factors. Half of the prison population is French citizens originally from French Guiana. Furthermore, French Guiana is one of the French regions most affected by poverty; according to the national institute for statistics, 50% of the population lived below the poverty line in 2017. Compounding the issue of precarious living conditions are difficulties in accessing rights and healthcare. Nearly 30% of patients were undocumented prior to incarceration and were not entitled to outpatient care. Little data is available regarding educational attainment, but in 2020, 80.9% of inmates were referred by the prison administration to undergo an illiteracy assessment conducted by teachers. Precarious living conditions, low socioeconomic status, low educational attainment, and difficulties accessing healthcare and rights are recognized factors contributing to poor health. In addition to these pre-incarceration vulnerabilities, there are difficult conditions of detention, such as overcrowding exacerbated by prison overcrowding.

In terms of health and infectious disease risks, there is a high prevalence of people living with HIV (PLHIV), at 3.8% in 2021, representing approximately 3% of PLHIV under care in French Guiana in 2021. Following an analysis of tuberculosis-related risk, it was found that nearly 10% of people who reported having active tuberculosis between 2008 and 2020 in French Guiana had been incarcerated at least once.

Zoonotic risk In 2010, the prison administration commissioned an agency to assess the health risks associated with the presence of tens of thousands of swallows at the CPG. In fact, since the early 2000s, a colony of swallows has chosen the CPG as its roosting site. Their presence at the prison varies in size depending on the season. These swallows migrate to Argentina or southern Brazil starting in October to nest there and return to French Guiana to spend the southern hemisphere winter between April and May. A census conducted by the French Guiana Bird Study and Protection Group in July 2009 recorded 52,367 birds, more than 98% of which were Chalybea swallows. From October to April, when the bulk of the colony migrates south, some so-called "sedentary" swallows nevertheless remain in the vicinity of and within the prison grounds. Over the past ten years, this colony of "sedentary" birds has grown to its current size of approximately 15,000 to 25,000 birds. Numerous measures have been taken to scare the swallows away or relocate them, and the CPG has enlisted the help of experts to implement these measures.

These measures-which are by no means exhaustive-included installing protective nets, using gunshots to scare them away, setting up electric wires and ultrasonic devices, deploying inflatable scarecrows (shaped like falcons), using gas cannons and repellents, and constructing a structure adjacent to the CPG in an attempt to relocate them.

Overall, these various measures have been unsuccessful, but there appear to be fewer swallows each year (approximately 25,000 during the 2020 season). The agency report highlighted the zoonotic risk and conducted a theoretical assessment of these risks (in addition to an assessment of noise and odor nuisances). Four zoonoses were identified and considered to pose a risk of transmission within the prison: Chlamydia psittaci infections, toxoplasmosis, histoplasmosis, and Q fever.

Few studies on the health of incarcerated individuals have been conducted at the correctional facility; one study was reportedly carried out in the early 2000s by the Pasteur Institute of French Guiana, but the results were never published, and as a result, little information is available. It appears that rodents were captured, but no cases of Q fever were detected. No swallows or bats were captured. The presence of these animals has been confirmed, as they are potential reservoirs and/or intermediate hosts of zoonoses. The zoonotic risk is real but currently poorly understood. To date, although little data is available regarding zoonotic risks, given the high risk in the general population, these risks must be taken into account among the prison population in French Guiana.

Zoonoses are a major public health issue in French Guiana. They encompass a wide range of infections: bacterial (Q fever, leptospirosis), viral (rabies), parasitic (Chagas disease, toxoplasmosis, leishmaniasis), and fungal (histoplasmosis). These infections are responsible for a large number of hospitalizations and deaths, both during epidemics (such as leptospirosis) and in routine clinical practice (Q fever accounts for 30% of hospitalizations for pneumonia in the territory).

Although it is supposed to be isolated from the outside world, the CPG does not appear to be spared from these zoonotic diseases. There appear to be factors facilitating the transmission of zoonotic diseases-such as vectors and animal reservoirs-combined with overcrowding, and a lack of air conditioning. An endemic-epidemic circulation of Q fever within the CPG has recently been described. The incidence rate of acute, symptomatic Q fever even exceeded that of the general population in 2020. Other zoonotic diseases may be circulating within the CPG, as noted in the health risk assessment report by the agency (2010). The presence of rodents and swallows at the CPG could facilitate the spread of psittacosis (Chlamydia psittaci infection), Q fever, or histoplasmosis, although this hypothesis has not yet been verified.

Five zoonoses of interest were selected for this study :

  • Q fever
  • Leptospirosis
  • Chagas disease
  • Histoplasmosis
  • Toxoplamosis

Study hypothesis We hypothesize that there is a risk of zoonotic disease transmission at the French Guiana Penitentiary Center (CPG). This study aims to assess the actual zoonotic risk among the CPG prison population in a systematic, comprehensive, and multidisciplinary manner. Five zoonoses of interest were selected based on their transmission cycle (presence of potential reservoirs or vectors within the prison) and their epidemiological characteristics.

Expected benefits

This study will make it possible to:

  • Objectively assess the risk of zoonotic diseases within the French Guiana correctional facility
  • Implement preventive, informational, or reassurance measures based on the results obtained.
  • Increase knowledge about zoonotic diseases in correctional settings.
  • Raise awareness among correctional staff and relevant authorities regarding the importance of health in correctional facilities.
  • Contribute to improving the health and living conditions of inmates.
  • Strengthen cooperation between health and justice stakeholders to foster an integrated approach to the prevention and management of infectious diseases in correctional facilities.
02

Conditions studied

  • Q Fever
  • Leptospirosis
  • Chagas Disease
  • Histoplasmosis
  • Toxoplasmosis Infection

Keywords

  • French Guiana
  • Prison health
  • zoonotic infections
  • correctional facility
  • cohort study
03

In context

Leptospirosis

25 studies on the registry are indexed under Leptospirosis; 11 are open to participants now.

This study's planned enrollment of 450 is above the median of 175 across 11 observational studies indexed under Leptospirosis.

Browse Leptospirosis studies →

Lead sponsor

Centre Hospitalier de Cayenne is the lead sponsor of 47 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults above 18 years old, incarcerated and housed at the French Guiana Correctional Facility for 15 days or less, from september 2026 to september 2028

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult aged 18 or older
  • Incarcerated and housed at the French Guiana Correctional Facility for 15 days or less.

Exclusion criteria

Exclusion Criteria:

  • Refusing to participate in the study
  • Pregnant women
  • Had already participated in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cohort participants

    Adults aged more than 18, in retention since at least 15 days in the French Guiana correctional facility in Cayenne

06

What researchers measure

Primary outcomes

  1. Incidence rate of zoonotic infections of interest (Q fever, leptospirosis, Chagas disease, histoplasmosis, toxoplasmosis) among participants who were seronegative for the infection in question at enrollment

    Number of new infections documented during follow-up divided by the person-time actually observed in detention at the correctional facility, from enrollment until the occurrence of the event, the last available visit, release, transfer, withdrawal of consent, or the end of follow-up at 12 months.

    Time frame: Baseline, Month 4, Month 8, Month 12

Secondary outcomes

  1. Seroprevalence of Q fever at baseline

    Proportion of participants with positive Q fever serology at enrollment

    Time frame: At Baseline

  2. Seroprevalence of leptospirosis at baseline

    Proportion of participants with positive Q leptospirosis serology at enrollment

    Time frame: At Baseline

  3. Seroprevalence of Chagas disease at baseline

    Proportion of participants with positive Chagas disease serology at enrollment

    Time frame: At Baseline

  4. Seroprevalence of toxoplasmosis at baseline

    Proportion of participants with positive toxoplasmosis serology at enrollment

    Time frame: At Baseline

  5. Risk factors for Q fever infection both inside and outside prison

    Association between exposure and the occurrence of Q fever, whether inside or outside prison

    Time frame: At Baseline, Month 4, Month 8 and Month 12

  6. Risk factors for leptospirosis infection both inside and outside prison

    Association between exposure and the occurrence of a lepstospirosis infection, whether inside or outside prison

    Time frame: At Baseline, Month 4, Month 8 and Month 12

  7. Risk factors of Chagas disease infection both inside and outside prison

    Association between exposure and the occurrence of the Chagas disease, whether inside or outside prison

    Time frame: At Baseline, Month 4, Month 8 and Month 12

  8. Risk factors of histoplasmosis infection both inside and outside prison

    Association between exposure and the occurrence of histoplasmosis infection, whether inside or outside prison

    Time frame: At Baseline, Month 4, Month 8 and Month 12

  9. Risk factors of toxoplamosis infection both inside and outside prison

    Association between exposure and the occurrence of toxoplamosis infection, whether inside or outside prison

    Time frame: At Baseline, Month 4, Month 8 and Month 12

  10. Influence of bioclimatic parameters

    Associations between bioclimatic parameters and incident infections, including, in particular, meteorological data (precipitation, humidity, temperature, wind direction)

    Time frame: At baseline

07

Study locations

1 site
08

References and documents

Publications

  • Le Turnier P, Mosnier E, Schaub R, Bourhy P, Jolivet A, Cropet C, Villemant N, Trombert-Paolantoni S, Berlioz-Arthaud A, Nacher M, Demar M, Picardeau M, Djossou F, Epelboin L. Epidemiology of Human Leptospirosis in French Guiana (2007-2014): A Retrospective Study. Am J Trop Med Hyg. 2018 Sep;99(3):590-596. doi: 10.4269/ajtmh.17-0734. Epub 2018 Jul 19. PubMed 30039781 ↗
  • Thill P, Eldin C, Dahuron L, Berlioz-Artaud A, Demar M, Nacher M, Beillard E, Djossou F, Epelboin L. High endemicity of Q fever in French Guiana: A cross sectional study (2007-2017). PLoS Negl Trop Dis. 2022 May 18;16(5):e0010349. doi: 10.1371/journal.pntd.0010349. eCollection 2022 May. PubMed 35584144 ↗
  • Bonifay T, Beillard E, Daniel M, Schiemsky V, Vierendeels E, Demar M, Pastre A, Hamiche K, Nacher M, Epelboin L. High incidence of acute Q fever among incarcerated people in Cayenne, French Guiana. Rev Inst Med Trop Sao Paulo. 2022 Jun 10;64:e42. doi: 10.1590/S1678-9946202264042. eCollection 2022. PubMed 35703611 ↗
  • Epelboin L, Chesnais C, Boulle C, Drogoul AS, Raoult D, Djossou F, Mahamat A. Q fever pneumonia in French Guiana: prevalence, risk factors, and prognostic score. Clin Infect Dis. 2012 Jul;55(1):67-74. doi: 10.1093/cid/cis288. Epub 2012 Mar 22. PubMed 22441648 ↗
  • Jolivet A, Cadot E, Florence S, Lesieur S, Lebas J, Chauvin P. Migrant health in French Guiana: are undocumented immigrants more vulnerable? BMC Public Health. 2012 Jan 19;12:53. doi: 10.1186/1471-2458-12-53. PubMed 22260085 ↗
  • Huber F, Vandentorren S, Merceron A, Bonifay T, Pastre A, Lucarelli A, Nacher M. Returning to care after incarceration with HIV: the French Guianese experience. BMC Public Health. 2020 May 24;20(1):754. doi: 10.1186/s12889-020-08772-9. PubMed 32448209 ↗
  • Huber F, Vandentorren S, Merceron A, Chaponnay A, Gadio G, About V, Pastre A, Nacher M. HIV-positive in the darkness of a correctional facility: more vulnerable and less treated. Int J STD AIDS. 2019 Apr;30(5):460-466. doi: 10.1177/0956462418816452. Epub 2019 Jan 10. PubMed 30630398 ↗

Individual participant data

Plan to share: No — Only aggregated data will be shared through scientific production

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 9, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07808775
Lead sponsor
Centre Hospitalier de Cayenne
Collaborators
European Founds for regional Developement (FEDER)
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Timothée Bonifay, MD
Contact
timothee.bonifay@chu-guyane.fr
+33594395050
Estelle Thomas, MPH
Contact
drci.promotion-cay@chu-guyane.fr
+33594395050
Timothée Bonifay, MD
study director · Centre Hospitalier de Cayenne, Inserm CIC 1424 Guyane-Amazonie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion